USA Financial Formulas Buys New Stake in Merck & Co., Inc. $MRK

Key Points

• USA Financial Formulas acquired 7,410 Merck shares worth approximately $891,000 during the first quarter. Hedge funds and institutional investors collectively own 76.07% of the company.
• Merck and Moderna reported positive Phase 3 results for their personalized cancer vaccine used with Keytruda in high-risk melanoma, prompting several analysts to raise price targets. However, RBC Capital Markets and Jefferies expressed caution over valuation, execution risks and Keytruda’s expected 2028 loss of exclusivity.
• Merck shares opened at $152.43, near their 12-month high, while the company announced a quarterly dividend of $0.85 per share, equivalent to a 2.2% annualized yield. Recent quarterly revenue rose 5.1% year over year to $16.61 billion and exceeded analyst expectations.

USA Financial Formulas purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund purchased 7,410 shares of the company's stock, valued at approximately $891,000.

Several other hedge funds have also bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Finally, High Note Wealth LLC boosted its stake in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Jefferies Financial Group cut Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a report on Wednesday. UBS Group increased their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday. The Goldman Sachs Group raised their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a report on Friday. Argus boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an "outperform" rating to a "sector perform" rating and upped their price target for the company from $142.00 to $150.00 in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $144.10.

Merck & Co., Inc. Trading Up 2.3%

MRK opened at $152.43 on Friday. The firm has a market cap of $376.07 billion, a P/E ratio of 121.94, a P/E/G ratio of 6.58 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $154.49. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a 50-day moving average of $128.09 and a 200 day moving average of $121.23.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. Merck & Co., Inc.'s payout ratio is 272.00%.

Insider Activity

In other news, EVP David Michael Williams sold 52,847 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares of the company's stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source